Cardiff Oncology’s (CRDF) “Buy” Rating Reaffirmed at HC Wainwright

Cardiff Oncology (NASDAQ:CRDF)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $14.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 297.73% from the stock’s previous close.

Separately, Piper Sandler boosted their target price on shares of Cardiff Oncology from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Friday, March 1st.

Cardiff Oncology Trading Down 21.4 %

NASDAQ:CRDF opened at $3.52 on Monday. Cardiff Oncology has a 1-year low of $0.94 and a 1-year high of $6.42. The business’s 50-day moving average price is $4.57 and its two-hundred day moving average price is $2.51. The firm has a market capitalization of $157.41 million, a price-to-earnings ratio of -3.91 and a beta of 2.02.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. Cardiff Oncology had a negative net margin of 6,594.92% and a negative return on equity of 54.54%. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.08 million. Sell-side analysts predict that Cardiff Oncology will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Cardiff Oncology

A number of large investors have recently added to or reduced their stakes in the business. PFG Investments LLC acquired a new stake in shares of Cardiff Oncology during the 1st quarter worth about $53,000. Callan Capital LLC raised its holdings in Cardiff Oncology by 37.2% in the 1st quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after acquiring an additional 11,600 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in Cardiff Oncology in the 1st quarter valued at about $1,351,000. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.